Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ImmuPharma ( (GB:IMM) ) just unveiled an update.
ImmuPharma PLC announced its participation in the Bio-Europe Spring Conference in Milan from March 17-19, 2025, a key event in the biopharmaceutical and life sciences sector. The company aims to leverage this opportunity to advance discussions with global BioPharma companies and secure commercial deals, enhancing its industry positioning and stakeholder engagement.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics. The company’s portfolio includes novel peptide therapeutics targeting autoimmune diseases and anti-infectives, with its lead program, P140, designed for the treatment of Systemic Lupus Erythematosus (SLE) and Chronic Idiopathic Demyelinating Polyneuropathy (CIDP).
YTD Price Performance: 183.33%
Average Trading Volume: 10,338,157
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £16.77M
For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.